CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 779 enrolled
Drug / intervention
Palbociclib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06086340
NCT06086340N/ACompleted
CompareCT.gov

Comparative Assessment of Overall Survival in Medicare Patients With HR+/HER2- Metastatic Breast Cancer Treated With Palbociclib in Combination With Aromatase Inhibitor (AI vs. AI Alone)

Pfizer·observational·Posted Oct 17, 2023·Updated Nov 18, 2025

In Brief

An observational study evaluating Palbociclib and Aromatase Inhibitor for Breast Cancer. Completed, enrolled 779 participants across 1 site.

Detailed Summary

A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy alone treatment in women or men aged 65 and older with newly diagnosed hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedOct 17, 2023
Enrollment StartSep 29, 2023
Primary CompletionJan 24, 2024
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.7 years ago

Interventions

Palbociclibdrug

Palbociclib with an aromatase inhibitor therapy

Aromatase Inhibitordrug

Aromatase Inhibitor Therapy